List of works - Martin H Voss

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

scientific article published on 11 February 2019

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

scientific article published on 29 May 2019

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

scientific article published in 2022

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

scientific article published on 20 August 2020

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

scientific article published on 05 April 2019

Author Correction: Towards individualized therapy for metastatic renal cell carcinoma

scientific article published on 01 October 2019

Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy number variations as drivers of disease progression

scientific article published on 27 March 2020

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

scientific article published on 07 October 2020

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

scientific article published on 01 June 2020

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

scientific article published on 25 September 2020

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

scientific article published on 4 January 2018

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

publication published on 26 May 2021

PTEN Expression, Not Mutation Status for , or , Correlates With Outcome on Everolimus in Patients With Renal Cell Carcinoma Treated on RECORD-3

scientific article published on 16 October 2018

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

scientific article published on 11 September 2020

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

scientific article published on 14 July 2021

Towards individualized therapy for metastatic renal cell carcinoma